Coya Therapeutics (NASDAQ:COYA) Cut to Strong Sell at Wall Street Zen

Wall Street Zen downgraded shares of Coya Therapeutics (NASDAQ:COYA – Free Report) from a sell rating to a strong sell rating in a research note issued to investors on Saturday morning,Wall Street Zen reports.

Several other equities research analysts also recently issued reports on the company. BTIG Research restated a “buy” rating and set a $16.00 target price on shares of Coya Therapeutics in a research report on Tuesday, September 15th. HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Coya Therapeutics in a research report on Thursday, November 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Thursday, October 15th. Chardan Capital reiterated a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a research note on Wednesday, August 12th. Finally, Roth Capital reissued a “buy” rating and set a $12.00 price objective on shares of Coya Therapeutics in a report on Monday, August 24th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $15.00.

Check Out Our Latest Stock Analysis on Coya Therapeutics

Coya Therapeutics Stock Down 4.2%

NASDAQ COYA opened at $3.00 on Friday. The firm has a market cap of $70.38 million, a P/E ratio of -2.16 and a beta of 0.70. The company’s 50 day moving average is $4.26 and its 200-day moving average is $4.57. Coya Therapeutics has a 12-month low of $2.72 and a 12-month high of $6.62.

Coya Therapeutics (NASDAQ:COYA – Get Free Report) last released its quarterly earnings data on Tuesday, November 10th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.11). Coya Therapeutics had a negative return on equity of 71.48% and a negative net margin of 643.44%. The business had revenue of $0.23 million during the quarter, compared to the consensus estimate of $0.11 million. Equities analysts expect that Coya Therapeutics will post -1.53 EPS for the current year.

Institutional Trading of Coya Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of COYA. Goldman Sachs Group Inc. grew its position in shares of Coya Therapeutics by 77.3% during the 3rd quarter. Goldman Sachs Group Inc. now owns 46,421 shares of the company’s stock valued at $233,000 after purchasing an additional 20,241 shares in the last quarter. Marshall Wace LLP increased its holdings in shares of Coya Therapeutics by 29.6% in the third quarter. Marshall Wace LLP now owns 323,849 shares of the company’s stock worth $1,622,000 after purchasing an additional 74,056 shares during the period. Allworth Financial LP increased its holdings in shares of Coya Therapeutics by 1,200.0% in the second quarter. Allworth Financial LP now owns 13,000 shares of the company’s stock worth $76,000 after purchasing an additional 12,000 shares during the period. AXQ Capital LP bought a new position in shares of Coya Therapeutics in the second quarter worth $116,000. Finally, Long Corridor Asset Management Ltd purchased a new stake in shares of Coya Therapeutics in the second quarter worth $227,000. 39.75% of the stock is currently owned by hedge funds and other institutional investors.

About Coya Therapeutics

(Get Free Report)

Coya Therapeutics is a clinical-stage biotechnology company developing therapies that aim to enhance the function of regulatory T cells, immune cells that help control inflammation. Its research focuses on potential treatments for neurodegenerative and other diseases associated with inflammation and immune dysfunction. The company’s development programs include biologic and cell-based approaches, with candidates under investigation for conditions including amyotrophic lateral sclerosis (ALS). These therapies remain in development; Coya does not have an approved commercial product.

Further Reading

Analyst Recommendations for Coya Therapeutics (NASDAQ:COYA)

Receive News & Ratings for Coya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.